Orexigen Therapeutics, Inc. (OREX) Stock Analysis 2011

By Tim - http://stockstobuy.org

The following is Orexigen Therapeutics, Inc. (OREX) technical analysis for February 3, 2011

Orexigen Therapeutics, Inc. (OREX) Support & Resistance Levels - 2/3/11

Resistance Levels: $2.75, $3

Support Levels: $2.50

Chart - Courtesy of www.stockcharts.com

Orexigen Therapeutics, Inc. (OREX) recently had a diet drug fail at the FDA which caused It's stock to drop significantly. Orexigen Therapeutics, Inc. (OREX) stock has had some nice support located at $2.50 so if you want to bet on this company getting their drug approved, look to buy around there. Orexigen Therapeutics, Inc. (OREX) has resistance on the upside located at $2.75 and $3.00. If OREX can break above $2.75, I think it can run back into the $3's.

For More Technical Analysis - Click Here

Today's Biggest Stock Gainers - Top 2011 Stock Gainers - Top 2011 Penny Stock Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Stocks for 2011

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Orexigen Therapeutics, Inc. (OREX) Stock Drops

By Tim - http://stockstobuy.org

The FDA has denied approval for a diet pill made by Orexigen Therapeutics, Inc. (OREX) on Tuesday. Orexigen Therapeutics, Inc. (OREX) stock fell 72.50% to $2.50.

FDA Issues Complete Response to New Drug Application for Contrave® for the Management of Obesity

Orexigen® Therapeutics, Inc. (Nasdaq:OREX - News) and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502.to - News) announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

The FDA noted concern about the cardiovascular safety profile of naltrexone/bupropion when used long-term in a population of overweight and obese subjects. Specifically, the letter stated that "before your application can be approved, you must conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with naltrexone/bupropion does not adversely affect the drug's benefit-risk profile."

So it looks like Orexigen Therapeutics, Inc. (OREX) will need to complete one more trial before this drug can be approved. All hope is not lost but Orexigen will certainly have it's work cut out for them! Resistance for the stock is located at $2.75

http://daytradingstockblog.blogspot.com

Orexigen Therapeutics, Inc. (OREX) FDA Approval Denied

By Tim - http://stockstobuy.org

The FDA has denied approval of a diet pill made by Orexigen Therapeutics, Inc. (OREX) this morning. Orexigen Therapeutics, Inc. (OREX) stock is tanking by 74% to $2.35.

FDA Issues Complete Response to New Drug Application for Contrave® for the Management of Obesity

Orexigen® Therapeutics, Inc. (Nasdaq:OREX - News) and Takeda Pharmaceutical Company Limited (Takeda) (TSE:4502.to - News) announced today that the United States Food and Drug Administration (FDA) has issued a complete response letter dated January 31, 2011 regarding the New Drug Application for Contrave® (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity, including weight loss and maintenance of weight loss.

The FDA noted concern about the cardiovascular safety profile of naltrexone/bupropion when used long-term in a population of overweight and obese subjects. Specifically, the letter stated that "before your application can be approved, you must conduct a randomized, double-blind, placebo-controlled trial of sufficient size and duration to demonstrate that the risk of major adverse cardiovascular events in overweight and obese subjects treated with naltrexone/bupropion does not adversely affect the drug's benefit-risk profile."

So it looks like Orexigen Therapeutics, Inc. (OREX) will need to complete one more test before this drug can be approved. All hope is not lost but Orexigen will certainly have it's work cut out for them!

http://daytradingstockblog.blogspot.com

Orexigen Therapeutics, Inc. (OREX) Stock Buy

By Tim - http://stockstobuy.org

The following is technical analysis on Orexigen Therapeutics, Inc. (OREX) stock for December 9, 2010

Orexigen Therapeutics, Inc. Support & Resistance Levels - 12/9/10

Resistance Levels: $8.80, $9.00

Support Levels: $8.50, $8

http://stockcharts.com - Chart

Orexigen Therapeutics, Inc. (OREX) stock fell below $9 yesterday and seemed to me like a good buy this morning at $8.60. I bought Orexigen Therapeutics, Inc. at $8.599 and will hold for a little while depending on where it goes. Orexigen Therapeutics, Inc. won FDA Panel support on Tuesday and expects the FDA to Approve the drug by the end of January 2011. If there are delays, Orexigen expects a decision by mid 2011. This stock could go to $7.50 or it could go back to $10 in the short term. Only time will tell.

For more Technical Analysis - Go Here

Today's Biggest Stock Market Gainers - Top 2010 Stock Gainers - Top 2010 Penny Stocks - Top 2009 Stock Gainers - Top 2009 Penny Stocks - Stocks for 2010

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/